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Pasireotide Long-Acting Release Treatment for Diabetic Cats with
Underlying Hypersomatotropism
R. Gostelow, C. Scudder, S. Keyte, Y. Forcada, R.C. Fowkes, H.A. Schmid, D.B. Church, and
S.J.M. Niessen
Background: Long-term medical management of hypersomatotropism (HS) in cats has proved unrewarding. Pasireotide, a
novel somatostatin analogue, decreases serum insulin-like growth factor 1 (IGF-1) and improves insulin sensitivity in cats
with HS when administered as a short-acting preparation.
Objectives: Assess once-monthly administration of long-acting pasireotide (pasireotide LAR) for treatment of cats with
HS.
Animals: Fourteen cats with HS, diagnosed based on diabetes mellitus, pituitary enlargement, and serum IGF-
1 > 1000 ng/mL.
Methods: Uncontrolled, prospective cohort study. Cats received pasireotide LAR (6–8 mg/kg SC) once monthly for
6 months. Fructosamine and IGF-1 concentrations, and 12-hour blood glucose curves (BGCs) were assessed at baseline and
then monthly. Product of fructosamine concentration and insulin dose was calculated as an indicator of insulin resistance
(Insulin Resistance Index). Linear mixed-eﬀects modeling assessed for signiﬁcant change in fructosamine, IGF-1, mean blood
glucose (MBG) of BGCs, insulin dose (U/kg) and Insulin Resistance Index.
Results: Eight cats completed the trial. Three cats entered diabetic remission. Median IGF-1 (baseline: 1962 ng/mL [range
1051–2000 ng/mL]; month 6: 1253 ng/mL [524–1987 ng/mL]; P < .001) and median Insulin Resistance Index (baseline:
812 lmolU/L kg [173–3565 lmolU/L kg]; month 6: 135 lmolU/L kg [0–443 lmolU/L kg]; P = .001) decreased signiﬁcantly.
No signiﬁcant change was found in mean fructosamine (baseline: 494  127 lmol/L; month 6: 319  113.3 lmol/L; P = .07)
or MBG (baseline: 347.7  111.0 mg/dL; month 6: 319.5  113.3 mg/dL; P = .11), despite a signiﬁcant decrease in median
insulin dose (baseline: 1.5 [0.4–5.2] U/kg; 6 months: 0.3 [0.0–1.4] U/kg; P < .001). Adverse events included diarrhea (n = 11),
hypoglycemia (n = 5), and worsening polyphagia (n = 2).
Conclusions and Clinical Importance: Pasireotide LAR is the ﬁrst drug to show potential as a long-term management
option for cats with HS.
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Hypersomatotropism (HS) is an increasingly recog-nized cause of diabetes mellitus (DM) in cats, with
prevalence estimates among diabetic cats ranging from
17.8% in Switzerland and the Netherlands1 to 24.8% in
the United Kingdom.2 Hypersomatotropism in cats usu-
ally results from excessive growth hormone (GH)
secretion from a functional somatotroph adenoma in
the pituitary gland.3 Growth hormone’s insulin-antago-
nistic eﬀects cause most cats with HS to be diabetic,
with many showing insulin resistance and persistent
signs of poor glycemic control despite exogenous insulin
administration.4 The mitogenic eﬀects of GH excess,
which are mediated by insulin-like growth factor-1
(IGF-1),5 can ultimately lead to body tissue prolifera-
tion and the clinical syndrome of acromegaly. In cats,
clinical acromegaly is associated with physical changes,
which can include prognathism inferior, broadening of
the face, cardiomyopathy, pancreatopathy, and degener-
ative arthropathy.6,7
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Treatment of HS in cats should aim to improve dia-
betic control and prevent progression of clinical acro-
megaly. Transsphenoidal hypophysectomy is the
recommended ﬁrst-line treatment for acromegalic
people.8 Hypophysectomy has successfully been used to
treat HS in cats,9,a but availability of surgery is limited.
In people, medical treatment is used to control HS
when surgery has failed, been declined, or is contraindi-
cated, and commonly used drugs include long-acting
forms of the ﬁrst-generation somatostatin (SST) ana-
logues, lanreotideb and octreotide.c,10 First-generation
somatostatin analogue treatment leads to biochemical
control of acromegaly in up to 54% of people, and
pituitary adenoma shrinkage in 30–50% of people.10,11
A minority of cats show a short-term decrease in
GH concentration when treated intravenously with
octreotide,12 but long-term medical management of HS
in cats has otherwise proven unrewarding, and treat-
ment with long-acting octreotide, or l-deprenyl, which
is a monoamine oxidase-B inhibitor, has failed to pro-
vide either clinical improvement and biochemical
improvement.13,d
Somatostatin binds to 5 receptor subtypes, named
somatostatin receptors (STTR) 1-5, which are variably
expressed in human pituitary tissue.14 Octreotide and lan-
reotide predominantly bind to STTR 215,16, and low
SSTR2 expression is a proposed reason for why some
acromegalic people fail to respond to these treatments.14
Preliminary work on pituitary STTR expression in cats
suggests that feline pituitary tissue expresses STTRs 1, 2,
and 5 and that pituitaries of cats with HS show greater
expression of STTRs 1 and 5 compared to STTR2.e This
ﬁnding could account for the poor response to octreotide
treatment shown by cats with HS.d
Recently, a multireceptor-binding STT analogue called
pasireotidef has been licensed as a long-acting, once-
monthly treatment for acromegalic people. Pasireotide
binds to a wider range of STTR subtypes than ﬁrst-
generation STT analogues. Pasireotide can bind to STTRs
1, 2, 3, and 5, and shows a 30-, 5- and 39-times greater
binding aﬃnity for STTRs 1, 3, and 5, respectively, com-
pared to octreotide, with a slightly lower aﬃnity for
STTR2.15 Pasireotide is eﬀective in some acromegalic peo-
ple who are resistant to ﬁrst-generation STT analogues,17
and short-acting pasireotide has been shown to provide
biochemical control, and improved insulin sensitivity,
when used as a short-term treatment in acromegalic cats.18
The current study was performed to assess whether long-
acting pasireotide (pasireotide LAR) could oﬀer eﬀective,
long-term treatment for diabetic cats with underlying HS.
Materials and Methods
This was an uncontrolled, 6-month, prospective, longitudinal
cohort study. The study was approved by the Ethics Committee of
The Royal Veterinary College (Royal Veterinary College Ethical
Approval Number URN2011 1120), and informed consent was
obtained from all participating owners. The study population was
formed from a convenience sample of cats diagnosed with HS at
The Royal Veterinary College (RVC) Acromegalic Cat Clinic. Trial
participation was oﬀered to cats diagnosed with HS at this clinic
between December 2011 and January 2014. Diagnosis of HS was
based on the presence of DM, documented pituitary enlargement
by computed tomography (CT), and a markedly increased serum
IGF-1 concentration of >1000 ng/mL. Serum IGF-1 concentration
was measured by a commercially available radioimmunoassayg that
had been previously validated in cats.19 This test has an upper limit
of quantiﬁcation of 2000 ng/mL, and values greater than this were
assigned a value of 2000 ng/mL for the purpose of data analysis.
On the day of admission, all cats received a physical examina-
tion, echocardiography, abdominal ultrasonography, urinalysis,
and measurement of CBC, serum biochemistry, fructosamine con-
centration, and IGF-1 concentration. Cats were excluded if these
tests revealed relevant underlying disease that might aﬀect success-
ful trial completion. This included diseases with poor prognosis
and diseases for which treatment was likely to interfere with trial
commitments. Cats then received pituitary imaging under sedation
by contrast-enhanced CT, as previously described,20 and a
dorsoventral pituitary height of >4 mm was considered to be con-
sistent with enlargement.21 Maximal pituitary height was recorded
for each cat. Other recorded baseline data included signalment,
bodyweight, and whether phenotypic signs of acromegaly were
present. Cats then underwent a 12-hour blood glucose curve
(BGC) while hospitalized using their usual insulin type and dose.
Blood glucose curves were carried out a minimum of 12 hours
after the above investigations and were performed by a handheld
glucometer previously validated for cats.h Curves consisted of a
reading taken every 2 hours over a 12-hour period, starting at the
time of morning food and insulin administration.
Cats received 8 mg/kg of pasireotide LAR by subcutaneous
injection before discharge and once monthly thereafter for a
planned 6-month follow-up period. Pasireotide LAR dose was
based on manufacturer’s recommendations. The majority of
included cats received 3 days of short-acting pasireotide treatmenti
between collection of their baseline data and their ﬁrst pasireotide
LAR dose. This short-acting pasireotide was given as part of a
separate, previously reported trial.18 Baseline data in these cats,
including their baseline BGC, were recorded before any pasireo-
tide, either short- or long-acting, was administered.
Monthly re-examination appointments and pasireotide LAR
administration were carried out at the RVC Acromegalic Cat Clinic.
Owners were asked to perform a 12-hour BGC on their cat at home,
or at their primary veterinary practice, in the 5 days before each re-
examination. At each re-examination, cats received a physical exam-
ination, and fructosamine and IGF-1 measurement in addition to
pasireotide LAR administration. Adjustments in insulin dose were
made based on the clinical opinion of the clinical trial team. Cats
who remained normoglycemic without insulin or oral antihyper-
glycemic medications (with the exception of low-carbohydrate diet)
for a minimum of 4 weeks were classiﬁed as being in diabetic remis-
sion. Cats received a repeated CBC, serum biochemistry measure-
ment, and abdominal ultrasound examination at the month 6 time
point, or sooner if clinically indicated, to monitor for abnormalities
that might be related to pasireotide treatment. Suspected adverse
events, the reason for any trial withdrawals, and any alterations
made in pasireotide LAR dosage were recorded. Cats remaining in
the study at the end of the 6-month period received repeated pitu-
itary imaging by contrast-enhanced CT at the month 6 time point to
assess for change in pituitary size. Change in phenotypic signs of
acromegaly was not evaluated as part of this study. It was thought
this would be challenging to assess because phenotypic signs of
feline acromegaly are often only subtle when judged by CT.20
Statistical Analysis
Average values for variables were reported as mean  standard
deviation (SD) for normally distributed data and as median with
range for non-normal data. Normality was judged by histograms,
normal plots, and Shapiro-Wilk tests.
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A linear mixed-eﬀects model with ﬁrst-order autoregressive
covariance structure was used to assess for signiﬁcant change in
fructosamine concentration, IGF-1 concentration, insulin dose
given at each twice-daily insulin administration (U/kg), and mean
blood glucose (MBG) concentration during BGCs over the 6-
month trial. Similar to the insulin sensitivity product assessed in
the previous short-acting pasireotide trial,18 for the purpose of this
study, the product of fructosamine and twice-daily insulin dose
(U/kg) was calculated as a surrogate indicator of insulin resistance,
referred to as the Insulin Resistance Index. This enabled documen-
tation of improvements in insulin sensitivity by integrating glyce-
mic changes with exogenous insulin dose changes. Change in this
variable over the duration of the trial was also assessed by a linear
mixed-eﬀects model with ﬁrst-order autoregressive covariance
structure, and values were logarithmically transformed before anal-
ysis to meet the model’s assumptions. For variables that showed a
signiﬁcant change, Fisher’s least signiﬁcant diﬀerence post hoc
comparison was used to assess pairwise diﬀerences between each
time point and month 0.
The maximal pituitary height at month 0 and month 6 time
points in cats completing the study was compared by a Wilcoxon
signed-rank test. Signiﬁcance for all tests was set at P < .05, and
all analyses were performed by commercial statistical software
packages.j ,k
Results
Thirty-three cats examined during the study period
were eligible for inclusion. Of these, 8 owners declined
trial participation and 11 owners decided to manage
their cat’s HS by hypophysectomy. Fourteen cats were
therefore enrolled onto the trial. Twelve of these cats
received 3 days of short-acting pasireotide before receiv-
ing their ﬁrst dose of pasireotide LAR.18 The remaining
2 cats were enrolled after the short-acting pasireotide
trial had ceased recruiting participants and so received
only pasireotide LAR.
Cat Characteristics at Enrollment
The study population consisted of 11 domestic short-
hairs, 1 domestic longhair, 1 Persian, and 1 Burmese. Ten
cats were neutered males and 4 were neutered females.
All cats had clinical signs of poor diabetic control, and 12
of the 14 cats had phenotypic changes consistent with
acromegaly on physical examination. Mean age at enroll-
ment was 9.9  2.2 years, and mean bodyweight was
5.8  1.1 kg. Complete blood cell counts revealed 1 cat
to have a stress leukogram, 1 cat to have mild, non-
regenerative anemia (PCV 21%; reference interval (RI)
24–45%), and 1 cat to have a moderate, mature neu-
trophilia, but revealed no other abnormalities. Serum
biochemistry analyses at trial entry revealed no abnor-
malities, apart from hyperglycemia in all cats. Abdominal
ultrasound ﬁndings noted at trial entry included bilateral
adrenomegaly (n = 9), bilateral renomegaly (n = 8),
hyperechoic hepatic parenchyma (n = 6), hepatomegaly
(n = 5), and suspected pancreatopathy (n = 4), with most
cats having more than 1 abnormality. For the purpose of
this trial, adrenomegaly was deﬁned as an adrenal width
of >4.8 mm, as proposed by a previous study.22
Cats had been receiving insulin treatment for a med-
ian of 231 (63–122) days before trial enrollment. All
cats were receiving twice-daily (q12h) insulin with 10
cats receiving porcine lente insulin,l 2 cats receiving
protamine zinc insulinm , and 2 cats receiving insulin
glargine.n No cats changed insulin type at the time of
starting pasireotide LAR, but 6 cats changed insulin
type later in the study period. Five cats were changed
from porcine lente to glargine treatment, and 1 cat was
changed from protamine zinc insulin to porcine lente
insulin. These changes in insulin treatment occurred a
median of 3 months (2–4 months) into the trial period.
Table 1 shows the number of cats remaining in the
trial at each time point and average values for variables
during the trial. Before starting pasireotide treatment,
median q12h insulin dose was 1.5 U/kg (0.4–5.2 U/kg),
median IGF-1 concentration was 1962 ng/mL (1051–
2000 ng/mL), and mean fructosamine concentration was
494  127 lmol/L. Mean blood glucose (MBG) concen-
tration during 12-hour BGCs before pasireotide treat-
ment was 347.7  111.0 mg/dL (19.3  6.2 mmol/L).
Median maximal pituitary height on CT at enrollment
was 7.2 mm (5.5–12.0 mm).
Response to Treatment
Three cats (21%) entered diabetic remission. A fourth
cat stopped insulin treatment for 15 days but then
became hyperglycemic again so did not meet criteria for
remission. In the 3 cats that achieved remission, insulin
was discontinued 89 days (n = 2) and 91 days (n = 1)
after their ﬁrst pasireotide LAR dose (Fig 1). All cats
that achieved remission continued to receive once-
monthly pasireotide LAR, and all completed the
6-month trial without a recurrence of DM. After trial
completion, 2 cats remained in remission until death 479
and 580 days after starting pasireotide LAR, and the third
cat is alive and in diabetic remission at the time of writing,
1420 days after starting pasireotide LAR treatment.
A signiﬁcant decrease was detected in IGF-1 concen-
tration (P=<.001), q12h insulin dose (P=<.001), and
Insulin Resistance Index (P = .001) over the trial per-
iod. Post hoc analysis revealed a statistically signiﬁcant
diﬀerence between month 0 and all subsequent time
points for all 3 variables (P-values shown in Table 1
and Figures 2, 3, and 4).
There was no signiﬁcant change in serum fruc-
tosamine (P = .07) or MBG during BGCs (P = .11)
over the study period (Table 1 and Figs 5 and 6). In
the 8 cats that completed the 6-month trial, maximal
pituitary height on CT examination changed by a med-
ian of 0.5 mm (1.8 to +1.3 mm) (P = .16).
Adverse Events
Various adverse eﬀects were recorded. Diarrhea, of
varying severity, was the most common adverse eﬀect
and was experienced by 11 cats (76%). Ten of these cats
developed diarrhea within 1 month of their ﬁrst pasir-
eotide LAR dose, and 1 cat developed diarrhea within
2 months of starting pasireotide LAR treatment. In 2
cats, diarrhea was transient and resolved within
2 months of starting treatment. Four cats had their
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diarrhea treated with one, or a combination, of exclusion
diet treatment (n = 4), pancreatic enzyme supplementa-
tion (n = 3), parenteral cobalamin injections (n = 1), and
soluble ﬁber supplementation (n = 1). Two cats had their
monthly pasireotide LAR dose decreased to 6 mg/kg in
the hope of improving their diarrhea. These management
changes caused a mild-to-negligible improvement. One
cat experienced 2 hypovolemic episodes that were
suspected to be secondary to bouts of diarrhea. Severe
diarrhea was a reason for trial withdrawal in 2 cats
(Fig 1). Six hypoglycemic events were documented in the
study population and occurred in 5 cats with 1 cat experi-
encing 2 episodes. Five of the 6 episodes were associated
with clinical signs. Other adverse eﬀects were worsening
polyphagia in 2 cats, a transient injection site reaction in
1 cat, and delayed hair regrowth in 1 cat.
Month 0 (Recruitment)
14 cats
Month 1
12 cats
Month 2
10 cats
Month 3
9 cats
Month 4
9 cats
Month 6
8 cats
Month 5
8 cats
Discontinued insulin and 
entered diabetic remission
3 cats
Number Remaining in Study Withdrawals and Major Reasons
2 cats
Diarrhea (1 cat)
Hypoglycemia (1 cat)
2 cats
DKA and worsened polyphagia (1 cat) 
Ongoing poor DM control (1 cat)
1 cat
Owner opted for 
hypophysectomy
1 cat
Diarrhea and worsened polyphagia
Fig 1. Flow diagram showing the number of cats remaining in the study at each time point, and the timing of study withdrawals and dia-
betic remission. Major reasons for study withdrawals are also shown. DKA, diabetic ketoacidosis; DM, diabetes mellitus.
Table 1. Number of cats remaining in the study at each time point and average values for variables monitored
during the trial.
Time Point
(month)
Number of Cats
Remaining
in Study
IGF-1
Concentration
(ng/mL)a
Twice-Daily
Insulin
Dose (U/kg)a
Fructosamine
Concentration
(lmol/L)b
MBG During
BGCs
(mg/dL)b
Insulin Resistance
Index
(lmolU/L kg)a
0 14 1962 (1051–2000)
n = 14
1.5 (0.4–5.2)
n = 14
494  127
n = 14
347.7  111.0
n = 13
812 (173–3565)
n = 14
1 12 909 (105–2000)***
n = 12
1.3 (0.1–1.3)***
n = 12
437  126
n = 12
302.2  159.8
n = 12
155 (43-774)***
n = 12
2 10 836 (415–1937)***
n = 10
0.4 (0.0–1.5)***
n = 10
406  116
n = 9
260.6  128.8
n = 9
99 (0–601)**
n = 9
3 9 1076 (386–2000)**
n = 9
0.2 (0.0–1.7)***
n = 9
483  152
n = 8
283.7  154.4
n = 9
146 (0–850)**
n = 9
4 9 1437 (841–1613)*
n = 9
0.1 (0.0–1.2)***
n = 9
370  143
n = 9
191.9  115.1
n = 6
40 (0–830) ***
n = 9
5 8 971 (520–1665)***
n = 8
0.3 (0.0–1.0)***
n = 8
399  132
n = 8
213.2  96.3
n = 6
29 (0–522)**
n = 8
6 8 1253 (524–1987)**
n = 8
0.3 (0.0–1.4)***
n = 8
416  125
n = 8
319.5  113.3
n = 6
135 (0–443)**
n = 8
aIndicates variable described using median (range).
bIndicates variable described using mean  standard deviation. n = number of patients with available measurement at that time point.
IGF-1, insulin-like growth factor-1; MBG, mean blood glucose; BGC, blood glucose curve. *, ** and *** indicate a statistically signiﬁcant
diﬀerence compared to Month 0 value (* indicates P < .05, ** indicates P < .01, *** indicates P < .001).
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Repeated CBC results at month 6 revealed no abnor-
malities, apart from mild eosinophilia in 1 cat.
Repeated serum biochemical analyses at month 6 also
revealed no abnormalities, apart from moderate hyperc-
holesterolemia in 1 cat, and a mild-to-moderate increase
in serum alanine aminotransferase (ALT) activity in 2
cats (126 U/L and 274 U/L; RI 20–100 U/L). Both cats
with ALT elevation remained clinically well, apart from
diarrhea in 1 cat, and neither showed other biochemical
indicators of hepatic dysfunction. One cat with severe
diarrhea underwent repeated serum biochemistry mea-
surement at the month 2 time point, but this revealed
no abnormalities. The only notable changes on repeated
abdominal ultrasonography at month 6, compared to
trial entry, were intestinal muscularis layer thickening in
2 cats, and gall bladder sediment in 1 cat. Both cats
with muscularis layer thickening experienced diarrhea
as an adverse eﬀect of pasireotide LAR treatment. The
cat with gall bladder sediment was 1 of 2 cats that
developed an increased serum ALT activity.
Trial Completion and Withdrawals
Eight cats (57%) completed the trial. Trial with-
drawals occurred after a median of 2 months
(1–5 months). Figure 1 shows the timing of each with-
drawal and the major reasons for which cats stopped
trial treatment. Withdrawals occurred for a variety of
reasons with some having more than 1 contributing fac-
tor. Reasons included severe diarrhea (n = 2), worsened
polyphagia (n = 2), failure of diabetic control to
improve (n = 1), and euthanasia after a hypoglycemic
event (n = 1) or episode of diabetic ketoacidosis
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Fig 2. Scatterplot showing individual serum IGF-1 concentra-
tions at each study time point. Central horizontal bar indicates
median value with error bars indicating interquartile range.
Dashed line shows recommended cutoﬀ for screening for HS in
cats (1000 ng/mL). *, ** and *** indicate a statistically signiﬁcant
diﬀerence compared to Month 0 value (* indicates P < .05, **
indicates P < .01, *** indicates P < .001).
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Fig 3. Scatterplot showing individual twice-daily insulin doses at
each study time point. Central horizontal bar indicates median
value with error bars indicating interquartile range. *** indicate a
statistically signiﬁcant diﬀerence compared to Month 0 value with
P < .001.
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Fig 4. Scatterplot showing individual Insulin Resistance Index
values (fructosamine 9 q12h insulin dose in U/kg) at each study
time point. Central horizontal bar indicates median value with
error bars indicating interquartile range. ** and *** indicate a
statistically signiﬁcant diﬀerence compared to Month 0 value
(** indicates P < .01, *** indicates P < .001).
Fig 5. Scatterplot showing individual serum fructosamine concen-
trations at each study time point. Central horizontal bar indicates
mean value with error bars indicating 1 standard deviation.
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(n = 1). One cat was withdrawn from the study after
the owner decided to manage its HS by hypophysec-
tomy rather than pasireotide LAR.
Discussion
This study found that once-monthly pasireotide LAR
treatment was associated with a signiﬁcant reduction in
IGF-1 concentration in diabetic cats with HS, suggest-
ing that pasireotide LAR signiﬁcantly improves exces-
sive GH production from feline pituitary
somatotrophinomas. Several pasireotide-treated cats
achieved long-standing diabetic remission, which rarely
occurs when diabetic cats with HS are treated with rou-
tine diabetic management alone.23 Cats receiving pasir-
eotide LAR experienced a signiﬁcant decrease in insulin
requirement and estimated insulin resistance, although
serum fructosamine concentration and MBG did not
signiﬁcantly change over the study period.
Previous attempts at long-term medical management
of HS in cats have proven unsuccessful,13,d making
pasireotide LAR the ﬁrst drug to show potential as a
long-term management option for feline HS. Octreotide
is the only other long-acting STT analogue to have been
assessed as a treatment for feline HS, but was found to
be ineﬀective.d Together, these ﬁndings are similar to
those of recent human trials, which have shown pasireo-
tide LAR to be superior to long-acting octreotide
treatment.17,24 This superiority has been attributed to
pasireotide’s wide receptor range and binding aﬃnity,
which allow it to accommodate variations in STTR
expression in patients’ somatotrophinomas. Octreotide
predominantly binds to STTR2, with lesser aﬃnity for
STTR3 and 5, whereas pasireotide binds to STTRs 1, 2,
3, and 5 and also shows a substantially greater binding
aﬃnity for STTRs 1, 3, and 5 compared to octreotide.15
The biochemical improvement shown by cats in this
study, and the poor previous experience with octreotide
treatment, supports that the pituitaries of cats with HS
have greater expression of STTRs 1 and 5 compared to
STTR2.e
That several cats in the current study achieved dia-
betic remission supports that pasireotide LAR oﬀers a
viable medical treatment option for HS in cats. Diabetic
cats with HS are most likely to achieve remission when
treated with a therapy that successfully addresses their
excess GH production.3 Diabetic remission can occur in
cats whose HS is treated by radiotherapy25 or hypo-
physectomy,9 with a recent study reporting a 78%
remission rate among cats who survived more than
17 days after hypophysectomy surgery.a In contrast,
treatment that addresses a cat’s DM alone, such as
insulin and low-carbohydrate diet, typically provides
inadequate glycemic control and little chance of
remission.23 The presence of remission among cats in the
current trial therefore supports that pasireotide LAR
eﬀectively reduces GH secretion from somatotrophino-
mas in cats and improves insulin sensitivity in treated
cats. Pituitary radiotherapy for HS in cats requires fre-
quent anesthesia and treated cats can have an unpre-
dictable response to treatment.25 Hypophysectomy
seems more predictably successful and requires only a
single anesthetic, but is oﬀered at reasonably few veteri-
nary centers, is associated with a postoperative fatality
rate of approximately 14% and requires lifelong, post-
operative hormone supplementation.a Pasireotide LAR
could therefore provide a viable alternative option for
control of HS in cats that are poor surgical or anesthetic
candidates, or have no access to hypophysectomy.
However, the common occurrence of diarrhea, need for
regular injections, and lack of information regarding
ideal dosing frequency still pose challenges to its use.
This study did not identify a signiﬁcant diﬀerence in
MBG, or fructosamine concentration, over the duration
of the trial. Lack of change in MBG could be sec-
ondary to how BGCs, from which MBG was calcu-
lated, were performed just before each cat’s next
monthly pasireotide LAR injection. As the LAR is
designed to last 1 month, it is likely that each cat’s pre-
vious pasireotide LAR treatment was waning by this
time leading to worsening diabetic control at the end of
each monthly treatment period and no apparent
improvement in MBG. The once-monthly dosing fre-
quency used in this trial was based on recommendations
from pasireotide LAR treatment in people, and further
work would be necessary to establish the optimum dos-
ing frequency in cats. Mean blood glucose results were
also likely to be artiﬁcially increased toward the end of
the study because 2 owners whose cats went into dia-
betic remission stopped performing monthly blood glu-
cose curves, opting instead to monitor their cat with
intermittent blood glucose measurements. Serum fruc-
tosamine concentration is generally accepted to reﬂect
cats’ glycemic control over the preceding 1–2 weeks26
and so sampling at the end of each monthly treatment
period is less likely to account for the lack of change in
serum fructosamine among recruited cats. This may
instead have been caused by many cats already having
a fructosamine concentration consistent with good-to-
moderate glycemic control at study entry, though only
when receiving relatively high dosages of exogenous
insulin.
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Fig 6. Scatterplot showing individual mean blood glucose values
during blood glucose curves at each study time point. Central hor-
izontal bar indicates mean value with error bars indicating 1 stan-
dard deviation.
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The fact that fructosamine and MBG remained
unchanged, despite a signiﬁcant decrease in insulin dose,
suggests that pasireotide LAR is associated with
improved insulin sensitivity in treated cats. A simple
Insulin Resistance Index was used to illustrate this in
the current trial and showed a signiﬁcant decrease at all
time points compared to time of enrollment. This index
has not been previously evaluated in cats, but the use of
reference methods for estimating insulin resistance, such
as the hyperinsulinemic euglycemic clamp or frequently
sampled intravenous glucose tolerance test, was thought
to be too invasive to justify their use on client-owned
cats. Simpler methods for evaluating insulin sensitivity,
such as the Homeostasis Model Assessment (HOMA)
and Quantitative Insulin Sensitivity Check Index
(QUICKI), have been used in diabetic cats.27 However,
the fasting insulin and glucose values required for these
calculations were not available for cats in this study.
This study revealed pasireotide LAR treatment to be
associated with various adverse eﬀects, the most com-
mon being diarrhea. Diarrhea is a common adverse
eﬀect of all long-acting STT analogue therapies in
people17,24 and is caused by STT’s widespread actions
in the gastrointestinal tract, which include suppression
of gastrointestinal exocrine secretions, inhibition of gas-
tric and gallbladder emptying, and alterations in intesti-
nal motility.16 Alopecia is a recognized adverse eﬀect of
pasireotide LAR treatment in people24, and 1 cat in the
current study showed delayed fur regrowth. This might
have been secondary to pasireotide treatment. Alterna-
tively, this cat could have been aﬀected by concurrent
hyperadrenocorticism, which is associated with DM,
insulin resistance and the presence of a pituitary ade-
noma, and has been reported to occur alongside hyper-
somatotropism in cats.28 This cat did not receive
pituitary–adrenal axis testing and did not have adreno-
megaly detected on abdominal ultrasound examination.
Hypoglycemia was the second most common adverse
event in the present study, whereas hyperglycemia and
development of DM are frequent adverse eﬀects in peo-
ple receiving pasireotide LAR.29 Pasireotide-associated
hyperglycemia is thought to result from decreases in
insulin and incretin secretion.30 In people, STT
decreases insulin secretion by binding to SSTR5 on
pancreatic b-cells,31 and pasireotide’s high aﬃnity for
STTR5 therefore reduces insulin secretion in treated
patients. The mechanism by which pasireotide decreases
incretin secretion is currently unknown. The frequency
of hypoglycemia in the current study and the fact that 3
cats entered diabetic remission suggest that STT’s eﬀect
on insulin and incretin secretion are mediated diﬀerently
in cats compared to people, or that improved insulin
sensitivity likely outweighs any decrease in insulin and
incretin secretion in treated cats.
Two cats in the current study developed a mild-
to-moderate increase in ALT activity while receiving
pasireotide LAR, and a third cat developed gall bladder
sediment. Increased serum ALT activity occurs in up to
5% of acromegalic people treated with pasireotide
LAR,32 whereas cholelithiasis and gall bladder abnor-
malities are more common adverse eﬀects of long-acting
STT analogue treatment in people. Gall bladder stones
or sediment develop in up to 45% of acromegalic peo-
ple treated with long-acting STT analogues, and often
occur in the absence of liver enzyme elevations.24,33 Sev-
eral factors contribute to the predisposition for
cholelithiasis among acromegalic people receiving long-
acting STT analogue treatment. Somatostatin and its
analogues reduce meal-stimulated cholecystokinin secre-
tion from the small intestine, which decreases gall blad-
der emptying.34 Also, acromegalic people receiving
octreotide are shown to have changes in bile composi-
tion, which predispose to cholelithiasis, including
increased biliary cholesterol content and alterations in
bile acid concentrations.35 All cats who developed
increased serum ALT activity, or ultrasonographic bil-
iary tract abnormalities, in this study remained clinically
well. However, it would nevertheless be advisable to
monitor cats receiving pasireotide LAR by intermittent
bloodwork and abdominal ultrasonography until the
long-term tolerability of pasireotide LAR in cats has
been better established.
Pasireotide LAR causes a signiﬁcant reduction in
tumor volume in up to 80% of treated people.24 This is
thought to be caused by STT, and STT analogues, hav-
ing both direct and indirect eﬀects on tumor growth.
Somatostatin analogues induce cell cycle arrest and
apoptosis through direct interaction with STTRs on
tumor cells.36,37 Indirect eﬀects include decreasing secre-
tion of growth-promoting hormones and factors, such
as GH and IGF-1, and by decreasing angiogenesis in
the local tumor environment.38 Octreotide decreased
tumor vascularity in a small series of people with
acromegaly,39 which might be caused by its ability to
decrease vascular endothelial growth factor expression.40
The failure to detect a signiﬁcant change in pituitary
height in the current study might be due to only a small
number of cats completing the 6-month treatment period.
Furthermore, pituitary tumor shrinkage is shown to
increase with time in people who receive STT treatment
over several years41 and so the relatively short duration
of this trial may have been insuﬃcient to observe a diﬀer-
ence. A larger sample size and longer cat follow-up could
therefore be required to demonstrate whether pasireotide
LAR treatment is associated with tumor shrinkage in
acromegalic cats.
This study has a number of limitations. People with
HS are often monitored using both GH and serum
IGF-1 concentration, whereas only serum IGF-1 con-
centration was measured in this study. This was ﬁrstly
due to lack of a commercially available assay for feline
GH. Secondly, GH release is pulsatile with a serum
half-life of less than 20 minutes in humans,42 whereas
IGF-1 is more constantly produced and has a half-life
of approximately 15 hours.8 IGF-1 concentration is
therefore the recommended screening test for HS in
people, rather than single GH measurement.43 IGF-1 is
the main mediator for GH’s mitogenic eﬀects,5 so an
IGF-1 concentration within normal limits is a treatment
goal in people with HS because this represents clinical
control of acromegaly.8 Interestingly, many of the cats
in the current study failed to achieve an IGF-1
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concentration below the recommended screening value
for HS (<1000 ng/mL)4 during the 6-month trial
(Fig 2), so might still have subclinical HS, despite pasir-
eotide LAR treatment. Increasing pasireotide LAR
dose, or dosing frequency, might result in more cats
achieving a normalized IGF-1 value, but it is possible
that adverse eﬀects might become dose-limiting in many
cats. Another limitation is that most included cats took
part in a 3-day trial examining the eﬀect of short-acting
pasireotide treatment before their ﬁrst injection of
pasireotide LAR.18 Short-acting pasireotide’s pharma-
codynamics have not been studied in cats, but it has a
half-life of approximately 12 hours in healthy people.44
If the rate of elimination is similar in cats, previous
short-acting pasireotide treatment is unlikely to have
aﬀected any patient values during this study. A propor-
tion of cats also changed insulin type during the study,
and it is possible this may have contributed to minor
changes in these cats’ diabetic control over the 6-month
period. Nevertheless, insulin treatment alone is rarely
successful in providing adequate glycemic control in
diabetic cats with HS, regardless of the insulin type,23
and it is therefore unlikely that any change in insulin
type was responsible for the changes in diabetic control
observed in the study population.
This study used a convenience sample formed from
diabetic cats diagnosed with HS at the RVC Acrome-
galic Cat Clinic. All owners were oﬀered hypophysec-
tomy for management of their cat’s HS, as an
alternative to trial enrollment, at the initial examina-
tion. It is possible that cats whose owners opted for
trial inclusion systematically diﬀered from those who
underwent hypophysectomy and that this resulted in
selection bias when forming the study population.
Treatment with pasireotide LAR was provided at no
cost to participating cats, and this ﬁnancial incentive is
likely to have had a major inﬂuence on many owners’
decision to partake in the trial. However, it is possible
that other factors, such as large pituitary tumor size,
might have caused clinicians to less strongly recommend
hypophysectomy in certain cats. In support of this the-
ory, a study of cats that underwent hypophysectomy at
the same hospital over the same time period revealed
them to have a smaller median pituitary height
(6.0 mm; range 4.0–10.6 mm) than cats in the current
study.a Pituitary mass volume is unrelated to IGF-1
concentration in cats with HS.45 However, cats with lar-
ger tumors could be predisposed to deterioration and
early trial withdrawal because of neurological compro-
mise from their mass.4 Although this potentially could
have negatively biased this study’s observed response to
pasireotide, no cats in the current trial were excluded
due to neurological deterioration.
Inclusion of a control group would have helped to sup-
port that the observed changes in recruited cats were
directly due to pasireotide treatment, rather than another
explanatory factor. Inclusion of a control group was con-
sidered ethically controversial because cats with HS typi-
cally experience persistent signs of poor diabetic control
when treated with routine DM management alone.23 The
fact that diabetic cats with HS predictably show a poor
response to routine diabetic treatment supports that the
changes observed in the current trial are most likely to be
related to pasireotide treatment. It is also possible that
some suspected adverse events recorded in this study were
actually unrelated to pasireotide treatment. However,
diarrhea was the most common adverse event in this
study and is also a common adverse eﬀect of long-acting
STT analogue treatment in people.17,24 This similarity
and the fact that several other adverse eﬀects observed in
this trial are also reported in people receiving pasireotide
LAR suggest that most adverse eﬀects in this study were
caused by pasireotide treatment. Finally, the pharma-
cokinetics of pasireotide LAR in cats are currently
unknown and require future investigation in order to
establish the optimum dosing protocol for pasireotide
LAR as a treatment for HS in cats.
In conclusion, this study shows pasireotide LAR to
be the ﬁrst drug to show potential as a long-term man-
agement option for diabetic cats with HS, with treated
cats showing a signiﬁcantly decreased IGF-1, improved
insulin sensitivity, and some cats achieving diabetic
remission. Diarrhea is a signiﬁcant adverse eﬀect and
further work is necessary to establish the optimum dos-
ing strategy to provide eﬀective diabetic control while
limiting adverse eﬀects.
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